Kristopher May, OD
Optometrist · Coldwater, MSNPI 1598758781
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Sight Sciences, Inc. at 58.6% of the total. Reporting peaked in 2024 at $54,458 and has fallen 66.6% since, to $18,204 in 2025. Among optometrist clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $642.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$134K
- Bausch & Lomb Americas Inc.$35K
- Alcon$25K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$17K
- Glaukos Corporation$15K
- Alcon Research LLC$1K
- plus $1K from 14 others
Across 66 payments — averaging $514.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$34K
What the payments were for
- Consulting fees$76,38033%
- Speaking & faculty fees$119,45052%
- Travel & lodging$22,50410%
- Food & beverage$10,1024%
- Entertainment$3400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 148 | $133,949 |
| Bausch & Lomb Americas Inc. | 78 | $35,057 |
| Alcon | 68 | $25,298 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 31 | $16,849 |
| Glaukos Corporation | 8 | $15,124 |
| Alcon Research LLC | 1 | $1,060 |
| Optos, Inc. | 4 | $340 |
| Topcon Healthcare, Inc. | 3 | $279 |
| Coopervision Inc. | 2 | $193 |
| Novartis | 3 | $163 |
| Johnson & Johnson Vision Care, Inc. | 1 | $136 |
| Oyster Point Pharma, Inc. | 1 | $106 |
| Quidel Corporation | 1 | $61 |
| Rxsight Inc | 1 | $53 |
| LKC Technologies, Inc. | 1 | $27 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$89,684
- OMNI$28,278
- INFUSE$16,491
- DAILIES$13,174
- RADIUS$12,044
- BIOTRUE ONE DAY$11,502
- BIOTRUE$11,399
- ULTRA$11,399
- TEARCARE SYSTEM$7,894
- TearCare$6,099
- ULTRA MULTIFOCAL TORIC$3,777
- Radius XR$3,080
- AcrySof$2,450
- TOTAL30$1,987
- Precision 1$1,729
- CyPass$1,590
- DAILIES TOTAL1$1,590
- AcrySof IQ PanOptix$1,458
- Centurion$398
- PanOptix$265
How this compares
$228,776 in reported general payments places this provider in the 95th percentile of 372 optometrist providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 22 | $17,439 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $9,866 |
| LumiganBimatoprost | 29 | $9,295 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $9,021 |
| VyzultaLatanoprostene Bunod | 24 | $7,761 |
| Travoprost | 40 | $4,788 |
| Brimonidine Tartrate | 61 | $1,125 |
| Latanoprost | 153 | $1,059 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $613 |
| Dorzolamide Hcl | 15 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $11 | $35,75468 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $14 | $9,86620 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $35,057 | $7,76124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 372 optometrist providers in Mississippi.
Other optometrist in Coldwater
- Alyssa MabrySenatobia$66K
- Roya AttarJackson$19K
- Deandre CarrByram$9K
- Michael ObrienSouthaven$9K
- George MarchbanksGulfport$9K
- William ArnoldMadison$9K
- Ramonica LewisClinton$8K
- Megan LottHattiesburg$8K
- Hal HillMadison$8K
- Raymond ShackelfordHernando$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.